Amniotic Vs. Autologous Sources

Stem Cell from Bone Marrow Aspirate vs. Amniotic Sources

Overview – This is an overview of the life changing potential of natural regenerative cells and processes in the body using Autologous Bone Marrow Aspirate Mesenchymal Stem Cells (“Your” Live Tissue) vs. Allogenic Amniotic Tissue Injections (Dead Tissue from another human source). Here are some of the pros and cons of the two processes:

Allogenic (foreign) Amniotic Tissue Injections (Dead Tissue)

Limited Growth Factors
Limited Growth Factors
Someone else’s cells
No live stem cells
Adverse effects
Not covered by insurance

Autologous Bone Marrow Aspirate Mesenchymal Stem Cells (“Your” Live Tissue)

Your own cells
Millions of live Mesenchymal Stem Cells
Abundant Growth Factors
No painful surgery
Not covered by insurance

Allogenic Amniotic Tissue Injections Vs. Autologous Bone Marrow Aspirated Concentrate Mesenchymal Stem Cell Regenerative Procedures

In simplest terms, the word “allogenic” means cells or tissue from an outside source – in other words, cells or tissue from another person that are injected into a patient’s body.

The word “autologous” refers to cells or tissues from the same body. In autologous treatments, cells and/or tissue from the patient’s own body are used.

Essentially, the difference between these two treatments is helping one’s own body self-heal or introduce an outside human tissue source in hopes of producing healing in the body.

Allogenic Amniotic Tissue Injections

Allogenic amniotic tissue injections are created from tissue from another person that has been frozen. Frozen tissue is dead tissue and therefore contains no live stem cells, which independent lab tests have confirmed.

Despite this, and the fact that none of the manufacturers of amniotic tissue claim that there are living stem cells in their products, there has been an explosion in the amount of providers advertising so-called “amniotic stem cell” injections.

Here are five key points:

  • Some physicians inject allogenic dead tissue into patients while claiming that they are injecting amniotic stem cells.
  • The placental tissue-derived products tested by the Interventional Orthopedics Foundation (IOF) are FDA regulated and sold directly to physician practices. Although not registered as live stem cell products, many physician websites tout the tissues as “stem cell therapy.”
  • Although these allogenic products contain no live stem cells, they exhibit a weak growth factor effect, which can help promote tissue repair. Therefore, patients may experience some improvement after these injections.
  • Growth factors can be obtained at a less expensive price and physicians should not be billing for stem cell therapy when injecting these dead tissue products into patients.
  • The IOF encourages physicians to use platelet rich plasma and bone marrow concentrate for biologic therapies. These are autologous treatments.

Autologous Bone Marrow Aspirated Concentrate Mesenchymal Stem Cell Regenerative Procedures

The Interventional Orthopedics Foundation, supports physician use of legitimate biologic therapies for orthopedic uses, such as super concentrated platelet and bone marrow concentrate. These autologous treatments – meaning the cells and tissue used come from the patient’s own body – are research-based in their effectiveness for patients.

At Catalyst Pain Solutions, we have seen our patients avoid surgery and experience very little down time with these treatments. They also typically avoid the long and painful rehabilitation periods that often follow surgeries to restore joint strength and mobility.

If you are considering surgery, arthroscopy or joint replacement, we invite you to explore all of your options, including RegenexxTM Procedures and other treatments available at Catalyst Pain Solutions. These are methods that help your own body heal itself naturally.

553340264_640 Amniotic Vs. Autologous Sources